Intercept Pharmaceuticals, based in San Diego, CA, is dedicated to developing innovative medicines for individuals facing rare and serious liver diseases. With a focus on advancing treatments for conditions like primary biliary cholangitis (PBC), Intercept's research portfolio targets novel scientific approaches to address high unmet medical needs in the field of liver health.
Since 2002, Intercept has been at the forefront of liver health research, leveraging a pioneering scientific platform to improve the lives of patients with rare liver diseases. Committed to building a healthier tomorrow, Intercept's team of over 300 employees works collaboratively to deliver impactful solutions and provide hope for those in need of advanced therapies.
Generated from the website